Abstract
Network Pharmacological Study of Yiyi-Fuzi-Baijiang powder in Treating Colorectal Cancer
Department of Oncology, the Second Affiliated Hospital of Nanjing University of Chinese Medicine, No. 23, Nanhu Road, Nanjing, Jiangsu 210017, China, 1Key Laboratory for Metabolic Diseases in Chinese Medicine, First Clinical Medical College, Nanjing University of Chinese Medicine, No. 155 Hanzhong Road, Nanjing Jiangsu 210023, China, 2Jiangsu Key Laboratory for Efficacy and Safety Evaluation of Chinese Material Medical, School of Pharmacy, Nanjing University of Chinese Medicine, No. 138 Xianlin Avenue, Nanjing Jiangsu 210023, China, 3Department of Traditional Chinese Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, Jiangsu 210029, China
Correspondence Address:
Department of Traditional Chinese Medicine, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, Jiangsu 210029, China, E-mail: xie-liqun@163.com
This investigation dealt with the analysis of the active ingredients of Yiyi-Fuzi-Baijiang powder in the treatment of colorectal cancer using computer network pharmacology technology to predict the mechanism of action. The chemical constituents and targets of Yiyi-Fuzi-Baijiang powder were obtained from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and the common targets in the treatment of colorectal cancer were obtained from Online Mendelian Inheritance in Man, Therapeutic Target Database and PharmGkb database. Excel was used to screen the molecular target and Cytoscape software was used to establish the network of Chinese medicine components target of Yiyi-Fuzi-Baijiang powder. The gene function and metabolic pathway were analyzed using the biological information annotation database. Nineteen components of Yiyi-Fuzi-Baijiang powder were found to interact with 121 target proteins of colorectal cancer, including progesterone receptor, prostaglandin G/H synthase 2, gamma-aminobutyric acid receptor subunit alpha-1, prostaglandin G/H synthase 1, nuclear receptor co-activator 2, beta-2 adrenergic receptor, sodium channel protein type 5 subunit alpha, alpha-1B adrenergic receptor. It is the target of Chaihushugansan in the treatment of post-stroke depression, mainly involving in neuroactive ligand-receptor interaction, endocrine regulated calcium reabsorption, TGF-β signaling pathway, Hedgehog signaling pathway, inflammatory mediator regulation transient receptor potential channels, cholinergic synapse, through the regulation of the nervous system, cell cycle, apoptosis, inflammatory regulation, cell communication and other biological processes to treat colorectal cancer. The possible mechanism of Yiyi-Fuzi-Baijiang powder in treating colorectal cancer was revealed by network pharmacological study, which laid a foundation for further elucidation of its action target.
